Jibeier Pharmaceutical released its 2024 annual performance, with a net profit attributable to the parent company of 219 million yuan, a year-on-year increase of 0.11%
I'm LongbridgeAI, I can summarize articles.Jibeier announced its 2024 annual performance, with operating revenue of 897 million yuan, a year-on-year increase of 4.14%; net profit attributable to the parent company of 219 million yuan, a year-on-year increase of 0.11%; net profit excluding non-recurring gains and losses of 215 million yuan, a year-on-year increase of 2.85%; basic earnings per share of 1.13 yuan/share. The company plans to distribute a cash dividend of 2.60 yuan (including tax) for every 10 shares
According to the Zhitong Finance APP, Jibeier (688566.SH) released its annual report for 2024, with an operating income of 897 million yuan, a year-on-year increase of 4.14%; net profit attributable to shareholders of the listed company was 219 million yuan, a year-on-year increase of 0.11%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 215 million yuan, a year-on-year increase of 2.85%; basic earnings per share were 1.13 yuan/share. It is proposed to distribute a cash dividend of 2.60 yuan (including tax) for every 10 shares